In two placebo-controlled trials of 757 adults with severe hypertriglyceridaemia, quarterly plozasiran cut median fasting triglycerides by 79% and 81% at 12 months (placebo-adjusted −45 and −47 points); pooled acute pancreatitis rates were 1 vs 5 per 100 patient-years.
RCTn = 757
Watts et al. Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis